ArrePath’s President & CEO, Kevin Krause, is a featured panelist on Antimicrobial Resistance: The Urgent Global Response at the World Medical Innovation Forum happening September 15-17, 2025 at the Encore Boston Harbor.

ArrePath announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor’easter Ventures, and new investor AB Magnitude. 

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award biotechnology company ArrePath US$3.7 million to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales.

Join us at ESCMID 2025 from April 11-15 in Vienna, Austria. Our CEO Kevin Krause, our CSO Alita Miller, and our Head of Chemistry Deidre Johns will be in attendance hearing about the latest breakthroughs in Infectious Diseases R&D

Join ArrePath’s Chief Technology Officer, Kurt Thorn, for a live webinar titled “Charting New Frontiers in Artificial Intelligence for Antibiotic Design” on April 3, 2025.

ArrePath today announced the appointment of Kevin Krause as President and Chief Executive.

ArrePath today announced that it has been awarded a £1 million non-dilutive grant from PACE (Pathways to Antimicrobial Clinical Efficacy) in support of its efforts to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, a growing global health threat.

ArrePath will be presenting at the BioNJ BioPartnering event on May 14th at Liberty Science Center in Jersey City, NJ!

Join us in the Delta Lab at 10:50 AM – 12:10 PM.

The BioNJ BioPartnering Conference is co-sponsored by J.P. Morgan, J&J Innovation, and Morgan Lewis, and hosted by the Jersey City Economic Development Corporation.

ArrePath will be attending the 34th European Congress of Clinical Microbiology & Infectious Diseases, which will take place in Barcelona, Spain from April 27-30.

ArrePath is pleased to be presenting at @MassBio 2024 Align
Summit w/ insights by @McKinsey & @LocustWalkPtrs. Register for a day full of partnering opps. w/
investors, panels & presentations from early-stage #Biotech and emerging AI/ML companies.
https://www.massbio.org/align